PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.
The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.
Read moreReference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic users.
Read moreBig news- a collaborative effort among scientists from the University of Texas at Arlington, Scottsdale Research Institute in Phoenix, Shimadzu Scientific Instruments in Maryland, and Millipore-Sigma in Round Rock, Texas, has led to the development of a new method for quantifying the potency of psilocybin and psilocin.
Read morePsychedelics may have a role in treating Alzheimer’s disease and related dementias.
Read the latest research insights and treatment approaches.
Read morePhantom pain and psilocybin are a growing area of research.
Psilocybin may be a treatment for this debilitating condition in the future.
Read moreAlso the trial’s rate of full remission, or a full cessation of symptoms, was five times greater than the placebo group, a marked and compelling difference in treatment outcomes.
Read moreIn a case report published in the journal Primary Care Companion to Central Nervous System Disorders, three Penn State clinicians describe a patient who experienced serotonin toxicity after combining antidepressants and anti-anxiety medications and psilocybin.
Serotonin toxicity, or serotonin syndrome, occurs when high levels of serotonin build up on the body; the condition can be fatal.
Read moreSmall clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Click here for the link to this article.
Read moreCYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.
The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.
Read more